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ABSTRACT TEXT 
There are important but ill-defined interactions between benign immune cell subsets 
and neoplastic B cells within follicular lymphoma (FL). Using the novel technique of 
correlation matrix analysis (CMA) of publicly available FL whole-tumor gene 
expression profiling (GEP) data, we have identified signatures of immune cell 
subsets. Overall survival correlated most highly with a model using signatures of 
macrophages, T cells, and stroma, which was able to add significantly to existing 
clinical prognostic tools. From our own data of a cohort of 43 FL tumors sorted into 
B-cell and non-B cell (NB) fractions for GEP, CMA of the tumor infiltrating NB 
fraction revealed additional immune cell subset signatures, including T follicular 
helper (TFH) cells. Comparison of gene signatures between FL and tonsils (n=24) 
suggested that TFH cells and macrophages are qualitatively distinct in FL from 
normal tissue. “Cross-correlation”, between FL NB fraction signatures and individual 
B fraction genes, suggests that TFH cells promote proliferation, germinal center 
stage differentiation, B-cell receptor signaling, and induction of CCL17 and CCL22 
by tumor B cells. This novel analytical approach may be broadly applicable to define 
gene signatures of rare immune cell subsets in the tumor microenvironment, 
 vi
determine their prognostic impact, discover novel therapeutic targets, and identify 
patients likely to benefit from therapies targeting tumor-stroma interactions.
 vii
TABLE OF CONTENTS 
Chapter 1 ............................................................................................................................ 1 
INTRODUCTION ............................................................................................................. 1 
Follicular Lymphoma ................................................................................................... 1 
Prognostic Systems for FL .......................................................................................... 2 
Indications for therapy of FL ........................................................................................ 5 
Watch and Wait in FL .................................................................................................. 5 
Immunotherapy ........................................................................................................... 6 
Chemotherapy ............................................................................................................. 8 
Interaction of the benign immune system and cancer .................................................. 9 
Follicular lymphoma evades endogenous antitumor immune responses ....................10 
Summary and Application of The Above Information To Thesis Project ......................13 
Chapter 2…………………………………………………………….…..………………………….32 
METHODS .....................................................................................................................16 
Cell Sorting .................................................................................................................16 
Quantification of DNA and RNA ..................................................................................19 
Determination of quality of RNA .................................................................................20 
RNA amplification and cDNA generation ....................................................................21 
cRNA Hybridization ....................................................................................................24 
Flow cytometry ...........................................................................................................26 
Data Analysis .............................................................................................................26 
Chapter 3 ...........................................................................................................................34 
RESULTS ......................................................................................................................34 
Correlation matrix analysis of whole-tumor GEP data reveals signatures of immune 
cell types and biological features in FL tumors ...........................................................34 
 viii 
Signatures of immune cell types in FL tumors are predictive of outcome ....................38 
Features of immune cell types in the FL microenvironment revealed by CMA of 
separated tumor cell suspensions ..............................................................................41 
Comparison of follicular lymphoma microenvironment with the normal lymphoid 
microenvironment .......................................................................................................46 
“Cross-correlation” analysis identifies interactions between tumor cells and immune 
cells in the immune microenvironment ........................................................................50 
Chapter 4 ...........................................................................................................................57 
DISCUSSION .................................................................................................................57 
Chapter 5 ...........................................................................................................................64 
STRENGTHS AND WEAKNESSES ...............................................................................64 
Chapter 6 ...........................................................................................................................66 
FUTURE DIRECTIONS ..................................................................................................66 
Vita ....................................................................................................................................68 
REFERENCES ..................................................................................................................69 
  
 ix
LIST OF FIGURES 
Figure 1. Co-stimulatory and co-inhibitory receptors expressed on T cells and their corresponding 
ligands on antigen presenting cells. 13 
Figure 2. Schematic of iterative filtering approach 29 
Figure 3. Hypergeometric Distribution Test 31 
Figure 4. Whole-FL tumor correlation matrix reveals outcome-correlated signatures 35 
Figure 5. The Y-chromosome gene signature, defined by correlation matrix analysis of whole-tumor 
GEP data from Dave et al, identifies patient gender. 36 
Figure 6. Correlation Matrix Heat Map Without Iterative Filtering 37 
Figure 7.  Overall survival in the three signature model without the IPI 38 
Figure 8. Permutation test for robustness of the 3-signature+IPI model 40 
Figure 9. Self Correlation heat map from the NB fraction 42 
Figure 10. Flow cytometry of CD68 expression compared with Mac_NK_mDC signature and CD68 
gene expression 43 
Figure 11. The CMA-defined TNB signature compared with a previous TFH signature 44 
Figure 12. The TNB signature compared with the Mac_NK_mDC signature 45 
Figure 13. Histogram of TNB and Mac_NK_mDC signature correlation in FL and Tonsils 47 
Figure 14. Heat map comparing FL and tonsil samples for the expression of previously-determined 
signatures of effector T cells (Teff) and TFH cells 49 
Figure 15. Cross-correlation heat map of B vs. NB fraction genes in FL tumors 51 
Figure 16. Correlation of CCL17 and CCL22 in the B tumor fraction with the TNB signature in the NB 
fraction 55 
 
  
 x
LIST OF TABLES 
Table 1. Multivariate Cox Model to determine the correlation with survival outcomes 38 
Table 2. B genes having expressions with top 20 highest correlation with the T-cell NB signature 53 
 
 
 
 xi
COMMONLY USED ABBREVIATIONS 
CR Complete response 
OS Overall Survival 
PFS Progression Free Survival 
PR Partial response 
SD Stable disease 
FL Follicular Lymphoma 
TFH T Follicular Helper 
NB Non-B Cell 
GEP Gene Expression Profiling 
CMA Correlation Matrix Analysis 
NHL Non-Hodkins Lymphoma 
IPI International Prognostic Index 
LDH Lactate Dehydrogenase 
ESR Erythrocyte Sedimentation Rate 
FLIPI Follicular Lymphoma International Prognostic Index 
GELF Group d’Etudades Lymphomes Folliculaires 
ORR Overall Response Rate 
FDA Food and Drug Administration 
KLH Keyhole-Limpet Hemocyanin 
GM-CSF Granulocyte-Macrophage Colony Stimulating Factor 
DFS Disease-Free Survival 
FFS Failure Free Survival 
CHOP Cyclophosphamide, Doxorubicin, Vincristine, Prednisone 
IR Immune Response 
IHC Immunohistochemistry 
PACE Prednisone, Doxorubicin, Cyclophosphamide, Etoposide 
pDC Plasmacytoid Dendritic Cells 
Mac Macrophage 
NK Natural Killer 
mDC Myeloid Dendritic Cells 
GSEA Gene Set Enrichment Analysis 
GC Germinal Center 
BCR B-cell Receptor 
 1
Chapter 1 
INTRODUCTION 
 
Follicular Lymphoma 
Follicular lymphoma (FL) is the second most common subtype of non-Hodgkin 
lymphoma (NHL) with ~15,000 new cases annually in the United States.(1) For reasons 
that remain unclear, the incidence of FL has increased in the United States and Europe 
over the past 2 decades.(2, 3) FL arises from maturing B cells within the lymph node 
germinal center. The neoplastic cells are typically organized in follicles (hence the name 
of the disease), and express germinal center-associated markers including BCL6, 
CD10, SERPINA9 (GCET1), and LMO2.(4) In addition, FL cells have a gene expression 
profile similar to that of centrocytes, a common cell found in the germinal center.(5) FL 
cells have an identical immunoglobulin (Ig) gene rearrangement pattern, which indicates 
that the malignant transformation occurs after VDJ gene recombination.(6, 7) Nearly all 
cases of FL feature the genetic hallmark of an acquired t(14;18)(q32;q21) translocation, 
resulting in deregulation of BCL2, a critical gene which regulates apoptosis and cell 
death. The t(14;18) translocation is generally thought to represent the initial genomic 
alteration in FL, but alone is insufficient for lymphomagenesis.(7) Up to 50% of healthy 
individuals harbor circulating cells that contain t(14;18) translocation, and rarely 
progress to FL. (8-12)  Peripheral blood cells which harbor the t(14;18) translocation in 
healthy individuals were thought to represent naïve B cells, but this assumption has 
been challenged by the discovery of many similarities to FL cells, including class-switch 
recombination and surface expression of IgM and IgD.(9) The significance of the 
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presence of the t(14;18) translocation in healthy individuals is unclear, and to date has 
not correlated with any prognostic or therapeutic relevance, but does suggests a 
potential common pre-malignant stage. It is noted that the incidence of FL, and the 
prevalence of t(14;18)-containing cells, both increase with age.(13) A subsequent 
discovery of MLL2 mutation, a histone methyltransferase gene, has been found in 89% 
of FL patients, representing a potential second founder mutation.(14) However, elegant 
studies utilizing exome sequencing of sorted FL patients samples has demonstrated a 
large amount of intratumoral diversity in FL, and that MLL2 mutations may be late 
common events, and not founder mutations.(6) In addition, these experiments identified 
mutations in another histone-modifying enzyme, CREBBP, that appear to be early 
events in the clonal evolution of FL. 
 
Prognostic Systems for FL 
Over 70% of newly diagnosed FL patients present with advanced disease, either due to 
early dissemination from the initial site or to a long asymptomatic phase prior to 
diagnosis. In the modern era, many patients are diagnosed with asymptomatic disease 
due to serendipitous imaging findings obtained for other indications. It is unclear if this 
potential lead time bias will ultimately have any impact on the natural history of FL. 
Follicular lymphoma is characterized by the Ann Arbor staging system, originally 
devised nearly 40 years ago to account for radiation field size. The system of scoring is 
based upon a stepwise anatomic progression of lymph node involvement, a pattern 
found commonly in Hodgkin’s lymphoma but not NHL, and thus its applicability to FL 
has been questioned.(15) Generally, it is suspected that patients whose extent of 
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involvement by FL appears to be only stage I (localized to a single lymph node) or stage 
II (localized to more than one lymph node on one side of the diaphragm) are likely to 
have undetectable disease at distant sites. A clinical trial conducted at M.D. Anderson 
found that patients with localized FL who were treated with aggressive chemotherapy 
and radiation still had a 24% chance of disease relapse at 10 years.(16) Indeed, clinical 
outcomes are not uniform within FL stages, confirming the suspicion that factors other 
than the simple location of the disease may affect outcomes. 
 
The original prognostic model for NHL was the international prognostic index (IPI), 
which accounted for clinically apparent factors.(17) The IPI incorporates age (>60), 
performance status (>2), lactate dehydrogenase (elevated), extranodal sites of disease 
(•2), and disease stage (•3) as adverse factors, and is able to separate patients into 
general categories. Unfortunately, these categories are heterogeneous in that patient 
the high risk group may do well, and low risk may do poorly, and thus their applicability 
is not predictive for a given patient. In 2000, the Intergruppo Italiano Linfomi 
retrospectively evaluated for these additional factors and created a prognostic 
model.(18) This initial model accounted for known risk associated factors including: pre-
treatment age, gender, number of sites of extranodal disease, B symptoms (fevers, 
chills, night sweats, significant weight loss), and the level of serum lactate 
dehydrogenase (LDH) and erythrocyte sedimentation rate (ESR) in the blood. Building 
upon their work, an international cooperative group created the Follicular Lymphoma 
International Prognostic Index (FLIPI) based on the data from over 4000 FL 
patients.(19)  This model included age (• 60 years vs < 60 years), Ann Arbor stage (III-
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IV vs I-II), hemoglobin level (< 12 dg/L vs • 12dg/L), number of nodal areas (> 4 vs < 4), 
and serum LDH level (above normal vs normal or below). By counting the adverse 
features present, patients were classified into three risk groups with 10 year overall 
survival (OS) of 70.7%, 50.9%, and 35.5%. The most predictive factor for the greatest 
risk of death evaluated in the multivariate analyses was advanced age. 
 
The FLIPI is widely utilized, but has several important weaknesses. First, the FLIPI was 
generated from a retrospective database analysis of patients that were treated with 
chemotherapies that did not include the currently ubiquitous immunotherapy rituximab. 
Second, the FLIPI dataset did not include significant data including the performance 
status and blood tests of ESR and β 2M. Third, the FLIPI had a primary endpoint of OS, 
which is challenging to study in an indolent disease like FL. The long natural history of 
the disease, serial responses to multiple effective therapies, and duration of follow up 
required to evaluate OS make this endpoint problematic. In order to attempt to 
overcome these known weaknesses, the International Follicular Lymphoma Prognostic 
Factor Project created the F2 study in 2003.(20) The primary endpoint of the model now 
referred to as FLIPI2 was progression free survival (PFS), which is the preferred metric 
in lymphoma clinical trials.(21) In multivariate analyses, factors found to achieve 
significance for increased risk included elevated blood β 2M, a single lymph node with a 
length greater than 6 cm, involvement of the bone marrow with FL, low hemoglobin level 
(< vs • 12dg/L), and advanced age (• vs < 60 years. Based on the number of factors 
present, patients were classified into three risk groups with 5 year PFS of 79.5%, 
51.2%, and 18.8%.  
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Indications for therapy of FL 
FL generally is highly sensitivity to multiple therapeutic classes, although the disease is 
considered incurable as relapse after initial response is nearly uniform.(22) Due to the 
fact that the majority of patients with FL have an indolent disease that is treatable but 
incurable, the option of deferred therapy has been found to have no negative impact on 
overall survival.(23, 24) In order to identify patients who do not require immediate 
therapy, the Group d’Etude des Lymphomes Folliculaires (GELF) criteria were 
developed from a prospective clinical trial.(25, 26) Patients with • 3 nodal sites with 
greatest length of • 3 cm, a single lymph node with a length of • 7 cm, symptomatic 
splenomegaly, B symptoms, and patients with cytopenias or effusions were found to 
have inferior outcomes with observation. As a result, the presence of any “GELF 
criteria” implies the need for therapy. 
 
Watch and Wait in FL 
Spontaneous regressions of biopsy proven sites of FL occur in 5 – 25% patients, which 
is likely related to the interaction of the intact immune-FL interaction.(27) In an 
immediate vs. delayed therapy clinical trial, patients with FL were randomized to 
chemotherapy or observation, and were found to have equivalent survival.(28) Of note, 
~10% of the observation patients did not require systemic therapy during the 10 years of 
follow up. Many other clinical trials have demonstrated similar excellent outcomes with 
delayed therapy.(29, 30) To date, there are no conclusive studies that show that a 
strategy of “watch and wait” results in inferior long term survival outcomes, despite the 
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current availability of many novel effective therapies. Further arguing for observation, 
therapy with a single chemotherapy drug or combination of drugs was shown to result in 
responses, but not a significant change in the overall survival of FL patients.(31) 
Modern therapy which includes biologically relevant agents has resulted in moderate 
improvements in overall survival, although disease eradication is still only achieved in 
an extreme minority, if any FL patients. This “responding, remission, relapsing” pattern 
remains poorly understood. 
 
Immunotherapy 
The immune system has been successfully manipulated to combat cancer for over 100 
years. In 1891, Dr. William Coley treated cancer patients with a mixture of bacterial 
toxins (Coley’s toxin), and reportedly achieved dramatic results in lymphoma and other 
malignancies. Other investigators could not achieve similar results, and thus early 
attempts at immune-based cancer therapy fell out of favor compared with radiation or 
chemotherapy.(32)  
Dr. Ronald Levy from Stanford and others have proposed that the use of monoclonal 
antibodies, a passive immunization strategy, could have efficacy via targeting 
lymphoma cell surface markers. In 1994, the phase I trial of IDEC-C2B8, a monoclonal 
antibody now commonly known as rituximab which targets the B-cell marker CD20, 
resulted in tumor regression in 40% of heavily pre-treated B-cell lymphoma patients.(33) 
The mechanism of action of rituximab is a combination of antibody-dependent cellular 
cytotoxicity, complement-mediated cytotoxicity, and direct signaling. The subsequent 
phase II and III rituximab trials evaluated 4 doses, administered once a week, of 
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375mg/m2 rituximab in relapsed low grade NHL and demonstrated overall response 
rates (ORR) of 46 and 48%, with a median duration of response of 10.2 and 13.0 
months, respectively.(34, 35) Of note, these large trials found rituximab to be very well 
tolerated with toxicities limited to allergic type reactions during the infusion. 
The Food and Drug Administration (FDA) approved immunomodulatory drug 
lenalidomide has shown promising efficacy in both newly diagnosed and relapsed 
FL.(36-39) A phase II trial in newly diagnosed FL patients found that lenalidomide and 
rituximab had an ORR of 98% and CR of 87%.(39-41) An ongoing phase III trial 
randomizes newly diagnosed FL patients who meet criteria for needing therapy to 
receive rituximab with lenalidomide or standard chemotherapy, followed by 
maintenance rituximab. 
Other immunomodulating agents have shown preliminary impressive activity against FL.  
We recently reported that pidilizumab, a monoclonal antibody directed against 
programmed death receptor 1 (PD1), a co-inhibitory receptor expressed by activated T 
cells, B cells, NK cells, and myeloid cells, had minimal toxicity and impressive efficacy 
when combined with rituximab in relapsed FL.(42) Pidilizumab is a humanized IgG1-
kappa recombinant monoclonal antibody that blocks the interaction of PD-1 with its 
ligands. The antitumor activity of the antibody in preclinical models was associated with 
increased numbers of CD4+ and CD8+ T cells and NK cells, and induction of 
immunologic memory. Based on our preliminary studies, administration of pidilizumab 
was expected to augment the naturally induced antitumor T-cell immunity in FL and 
enhance ADCC mediated by natural killer (NK) cells in the presence of rituximab. It was 
hypothesized that activation of both innate (NK cells) and adaptive (T cells) arms of the 
 8
immune system would likely minimize the emergence of immune escape variants and 
lead to improved remission duration. Indeed, we found that the overall response rate 
(ORR) of pidilizumab and rituximab was 66% (19/29) and the complete response (CR) 
rate was 52% (15/29).(42) In comparison, previously reported data in a similar 
population found rituximab alone to result in an ORR of 40% and CR rate of 11%.(43) 
Tumor immunoglobulin (idiotype, Id) is expressed in a clonal fashion on FL cells and 
has been demonstrated as safe and immunogenic in Phase I/II vaccination trials.(44-51) 
In a randomized, double-blind multicenter phase III clinical trial, patient-specific tumor-
derived Id protein was conjugated with a carrier protein (keyhole-limpet hemocyanin, 
KLH) and administered together with an adjuvant (granulocyte-macrophage colony 
stimulating factor, GM-CSF) to patients with advanced stage, previously untreated FL, 
in CR following standard induction chemotherapy.(52) Patients receiving vaccination 
with Id-KLH+GM-CSF had a significantly prolonged disease-free survival (DFS) when 
compared with the control group that received a non-specific immune stimulant 
(KLH+GM-CSF). This trial demonstrated the first positive result for a Phase III vaccine 
trial against lymphoma. Although significant, the therapeutic benefit of Id vaccination 
was small, and no change in overall survival was detectable.  Further improvements to 
cancer vaccine therapy are needed if it is to be a viable treatment strategy for patients 
with FL. 
Chemotherapy 
Follicular lymphoma is generally sensitive to chemotherapy, with numerous 
combinations demonstrating significant activity over the past 40 years. A retrospective 
review from M. D. Anderson Cancer Center found that over 25 years, each subsequent 
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generation of initial therapy, outcomes for patients with FL improved (both failure free 
survival (FFS) and OS).(53) Rituximab-based therapies had not yet reached their 
median FFS and OS, but appeared to result in a significant improvement in outcomes.  
The addition of rituximab to chemotherapy is known to be superior to chemotherapy 
alone.(54) As a result, rituximab is nearly ubiquitous in FL therapies, alone and 
combined with chemotherapy. A trial by the German Low-Grade Lymphoma Study 
Group randomized FL patients to CHOP with or without rituximab and found improved 
outcomes with the rituximab treated patients.(55) 
Interaction of the benign immune system and cancer 
It is now established that that the innate and adaptive immune systems can prevent the 
development of or eradicate tumors (cancer immunosurveillance or cancer 
elimination).(56, 57) Multiple studies have demonstrated that deficiencies of various 
immune components (such as interferon gamma or FasL) increase the rate of 
development of malignancies, including lymphomas.(58, 59) Mice lacking recombinase 
activating gene (RAG2), an essential gene for somatic rearrangement of lymphocyte 
antigen receptors, have a total lack of peripheral effector T cells, B cells, and NK/T cells. 
In a RAG2 deficient mouse model, Shankaran et al. found that the development of 
sarcomas after carcinogen exposure was significantly increased as compared to RAG2 
wild type mice, which along with other similar studies definitively established the 
principle of cancer immunosurveillance/elimination. 
Beyond prevention or eradication, the immune system can also modulate the immune 
profile of the tumor cells. Tumors from immune deficient models can be rejected when 
transplanted into immune competent models, speaking to their being more 
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immunogenic than those which developed in the presence of a functional immune 
system (cancer immunoediting).(56, 59) In order for cancer to escape the 
immunosurveilance or elimination in an immune competent host, malignant cells may 
display fewer antigens, and thus be less immunogenic.(60) In addition, cancers have 
also been shown to express inhibitory T-cell receptors, such as CTLA-4 and PD-1, 
which result in an immune tolerance phenotype, and eventual progression of 
cancer.(61) Those cancer cells with the ability to impair an immune surveillant response 
would have a large evolutionary advantage in comparison to their immune regulated 
counterparts, and thus the immune system provides a selection pressure. Together, 
these data speak to the “cancer immunoediting hypothesis” with three phases in the 
tumor modulation process: the “three Es of cancer immunoediting”: elimination, 
equilibrium, and escape.(62) 
 
Follicular lymphoma evades endogenous antitumor immune responses 
Follicular lymphoma has a relatively unique biology. Patients may have durable stable 
disease, spontaneous regressions, or even remissions, and yet the majority of patients 
eventually suffer disease progression. This unusual behavior for a malignancy is related 
to the complex interaction between the benign immune system and FL. This “waxing 
and waning” clinical course suggests that FL may go through an equilibrium phase 
where tumor progression is impeded or partly reversed by the immune system. 
Eventually, escape mechanisms develop resulting in progression of FL.  
Numerous recent studies support the hypothesis that the immune system plays a 
significant role in the control of FL. Among types of NHL, FL has a relatively high 
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proportion of non-neoplastic immune cells infiltrating involved lymph nodes (T, NK, and 
monocytes/macrophages). The extensive differences between neoplastic B cells and 
non-neoplastic cells may allow the overall gene expression profiles, determined by 
microarrays on the whole tumor, to be de-convoluted into “signatures” that are 
attributable to different elements within the tumor. Indeed, the landmark GEP study of 
FL by Dave et al. identified multiple signatures, two of which were attributed to 
infiltrating T cells and macrophages, with respectively positive and negative effects on 
outcome, adding to the effect of clinical prognostic tools.(63) Of note, this study did not 
find a predictive signature which could be assigned to the neoplastic FL cells, in 
contrast to other types of cancers. The prognostic significance of immune-response 
signatures has largely been validated by subsequent studies using microarrays and 
comparable techniques to measure mRNA (qRT-PCR),(64) including in patients treated 
with Rituximab,(65) and is among the evidence that the immune environment is an 
important determinant of outcome in FL. Although Dave et al. observed that “the 
immune-response 1 signature is not merely a surrogate for the number of T cells in the 
tumor-biopsy specimen, since many other standard T-cell genes…were not associated 
with survival,” to date GEP has not revealed specific mechanisms affecting the immune 
response in FL. 
Further speaking to the immune-FL relationship, an increased level of CD8+ T-cells in 
FL involved lymph nodes correlated with an improved prognosis.(66) In addition, the 
prognosis of patients with FL is positively correlated with an immunosurveillance pattern 
(CD8+ T cells) and negatively with an immune-escape pattern (CD57+ T cells).(67)  
Finally, tumor-specific T cells can be isolated from the tumor microenvironment and 
 12
peripheral blood in patients with FL.(68, 69) Together, these data suggest that an 
endogenous antitumor immune response is present in patients who harbor FL, but 
eventually becomes ineffective at controlling the tumor. This escape by the tumor is 
likely due to the development of various immunosuppressive mechanisms in the tumor 
microenvironment. 
Over the past decade, there have been significant advances in our understanding of the 
exceedingly complex and tightly controlled interaction of immune stimulating and 
inhibiting receptors.(70) Importantly, tumor-specific effector T cells have been found to 
be impaired by immunoregulatory mechanisms in the tumor microenvironment in 
various cancer models.(71) Cancers, including FL, are now known to modulate tumor-
beneficial immunosuppressive mechanisms which have the potential to result in 
progression from immune “equilibrium” to the “escape” phase.(61, 72, 73) Important 
inhibitory pathways that decrease tumor-specific T-cell effector function include extrinsic 
suppression by regulatory T cells (Tregs), direct inhibition through inhibitory ligands 
(Figure 1), and soluble factors such as transforming growth factor β  and interleukin (IL)-
10.(71)  
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Figure 1. Co-stimulatory and co-inhibitory receptors expressed on T cells and their 
corresponding ligands on antigen presenting cells. (Adapted from (70)) 
  
Summary and Application of The Above Information To Thesis Project 
Gene expression profiling (GEP) provides a wealth of high-content molecular data 
regarding the genomic state of tumors, which are complex mixtures of cancer and non-
cancer cells. In the landmark study by Dave et al., whole-tumor GEP data from 191 
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pretreatment samples of FL patients were utilized to seek features (predictors) which 
significantly correlated with OS.(63) A model based on two multi-gene signatures (one 
favorable, the other unfavorable) was found to add to the predictive power of the IPI. 
Remarkably, neither of these signatures was determined to originate from tumor B cells, 
but instead from benign tumor-infiltrating immune cells. As the signatures contained 
numerous genes related to the immune system, they were named immune response 
(IR)-1, attributed to T cells (OS-favorable), and IR-2, attributed to macrophages (IR-2, 
OS-unfavorable). The IR-1 signature “included several T-cell restricted genes but was 
not merely a measure of the number of tumor-infiltrating T cells, since a signature of 
pan-T-cell genes was not associated with survival.”(63) The conclusion of this statement 
is that the outcome in FL could be influenced by differences in infiltrating T cells, not 
only quantitative (i.e., their frequency) but also qualitative, such as proportions of the 
multiple T-cell subsets and physiologic states now known. Subsequent studies, most 
employing immunohistochemistry (IHC), have validated prior data regarding a role of 
the host immune microenvironment as a major determinant of outcome in FL, but 
consistent evidence is lacking for the cell types and mechanisms involved. 
In the 10 years since the study of Dave et al. was published, there have been significant 
advances in the understanding of both the immune system and its interaction with 
cancer. Knowledge of basic and tumor immunology has rapidly evolved, including the 
identification of multiple T-cell subsets and physiologic states of immune cells (e.g., T-
cell exhaustion, and states of macrophage polarization). In particular, the T follicular 
helper (TFH) cell, first reported in 2000, has been identified as a critical promoter of 
normal germinal center B cells. However, the ability of GEP to discover interactions 
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within and between the tumor cell and host immune cell compartments of FL, and their 
impact on survival, greatly depends on the technical and analytical methods employed. 
When GEP data derives from whole (unseparated) tumor samples, as used by Dave et 
al., the cell type(s) from which individual mRNA transcripts originate is not readily 
apparent. However, newer methods applied to GEP data from whole tumor biopsies, 
including correlation matrix analysis, are able to identify the relative proportions of T-cell 
subsets and other non-neoplastic cells infiltrating the tumor, and their correlation with 
outcome.(74) We report here our results from applying these methods to the data of 
Dave et al., as well as results from an independent series of FL tumors in which GEP 
was performed after separation into B-cell and non-B-cell fractions. 
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Chapter 2 
METHODS 
Cell Sorting 
Follicular lymphoma tumor biopsy samples were obtained from patients treated on the 
BiovaxID phase III idiotype vaccine clinical trial.(75) All tissue samples were obtained 
after written informed consent was obtained from patients through this institutional 
review board-approved protocol. Samples derived from a pre-treatment biopsy, 
obtained in part for idiotype vaccine generation, were processed into single cell 
suspension and viably preserved in -80oC refrigeration until removal for this project. All 
patients were subsequently treated with PACE (prednisone, doxorubicin, 
cyclophosphamide, etoposide)(47) chemotherapy for 6 cycles. If a patient achieved a 
clinical response which proved durable for at least 6 months, he/she was subsequently 
randomized to receive one of two adjuvant therapies: idiotype vaccination with immune 
stimulation vs. immune stimulation alone. 
A single sample vial for a given patient was identified by a patient-specific barcode and 
removed from -80oC refrigeration and immediately placed in a 37oC water bath. After 2 
minutes, 2ml of “Thawing Media” was added. “Thawing Media is defined as: 
RPMI liquid medium with 1x Glutamax = 500 mL bottle, added: 
1. HEPES buffer 1M – 10 mL or 20mM,  
2. sodium pyruvate 100mM – 5mL or 1mM,  
3. Penicillin 10,000 U/mL + Streptomycin 10,000 ug/ml – 5mL 
4. Gentamycin 10mg/ml – 500 uL 
5. 2-Mercapto Ethanol stock – 1000X – 500uL 
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6. 125mL of heat inactivated fetal bovine serum 
Cells were allowed to stand at room temperature for an additional 2 minutes prior to 
being centrifuged at 4oC with 1500 RPM for 10 minutes. The supernatant was removed, 
and the cell pellet was re-suspended in 2ml of MACS buffer (Miltenyi), and again 
centrifuged at 4oC with 1500 RPM for 10 minutes.  The supernatant was removed, and 
the cell pellet was re-suspended in 10ml of MACS buffer. After gentle vortexing to 
ensure relatively homogeneity of suspended cells, a 2ml aliquot was removed and 
placed in a separate vial.  Both the 8ml and 2ml samples were centrifuged at 4oC with 
1500 RPM for 10 minutes, and supernatant was discarded. The 8ml sample (referred to 
as “Non-B”) had 5ul of both Miltenyi CD19 and CD20 MicroBeads added per 1e7 cells, 
along with 90ul of MACS buffer and was gently vortexed for 30 seconds. The 2ml 
sample (referred to as “B”) had 10ul of Miltenyi CD3 MicroBeads per 1e7 cells added, 
along with 90ml of MACS buffer and was gently vortexed for 30 seconds. Both vials 
were then placed in an 8oC refrigerator for 30 minutes.  While the cells were incubating, 
the LD columns (Miltenyi) were prepared by placing them in the magnetic field of a 
MACS separator, and rinsing the LD column with 2 mL of MACS buffer.  The cells were 
removed from the refrigerator and washed by adding 1mL of MACS buffer, and 
centrifuged at 4oC with 1500 RPM for 10 minutes. The supernatant was removed, and 
the cell pellet was re-suspended in 500ul of MACS buffer. The labeled cells and MACS 
buffer wash were then added to the LD column in MACS separator, and the elution was 
collected (negatively selected cells). The column was washed with an additional 1 mL of 
MACS buffer twice to ensure elution of the maximal amount of unbound cells.  The 
column was then removed from the magnetic separator, placed in a new collection tube, 
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and washed with gentle manual pressure to elute 1.5 mL of MACS buffer to allow 
collection of the positively selected cells. 
The negatively selected cells were counted and assessed for viability based with trypan 
blue dye uptake. The cells were then aliquoted in 1e6 portions and placed in the 
centrifuge at 4oC with 1500 RPM for 7 minutes, and the supernatant was discarded. The 
cell pellet was snap frozen in -80oC and stored until all desired samples had undergone 
the above process. 
Prior to freezing, a portion of the cells were set aside for flow cytometry evaluation 
(~1e5 cells) from unsorted, negative and positive selection of both the CD19 and CD20 
and the CD3 populations. These cells were then assessed for purity with labeling with 
5uL CD3 PE and CD20 PerCP, along with 1uL of Kappa FITC via standard flow 
cytometry methods, and analysis with FloJo software. 
Nucleic acid extraction: 
Samples with an adequate number of negatively selected cells (>= 1e6 cells) were 
thawed for nucleic acid extraction. Vials were removed from the -80oC freezer and 
placed in ice for transportation to the bench. Immediately after arrival, 350uL of Buffer 
RLT Plus (Qiagen - AllPrep DNA/RNA Mini) was added to disrupt the cell membrane 
and cellular enzymes which may destroy nucleic acids. The vial was gently flicked to 
ensure the pellet was completely dissolved in buffer, and the homogenized lysate was 
then transferred to an AllPrep DNA spin column. The column was placed in a 2 mL 
collection tube, and then centrifuged at 10,000RPM for 30 seconds.  
The AllPrep DNA spin column was then transferred to a new collection tube and stored 
at room temperature. The flow through from the initial column wash had 350 uL of 70% 
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ethanol added, and was mixed well by pipetting up and down gently. The now ~700uL 
mixture, including any precipitate, was transferred to an RNeasy spin column placed in 
a 2 mL collection tube, and centrifuged at 10,000 RPM for 15 seconds. The flow through 
was processed for microRNA collection, and stored for future potential studies. The 
RNeasy spin column then had 700uL of Buffer RW1 (Qiagen) added, and was 
centrifuged at 10,000 RPM for 15 seconds, with the flow through being discarded. The 
RNeasy spin column then had 500 uL of Buffer RPE (Qiagen) added and was 
centrifuged at 10,000 RPM for 15 seconds, with the flow through discarded. An 
additional 500 uL of Buffer RPE (Qiagen) was then added to the RNeasy spin column, 
centrifuged at 10,000 RPM for 2 minutes, and the flow through was discarded. To dry 
the column completely, the RNeasy spin column was centrifuged at full speed for 1 
minute, and then placed in a new 1.5mL collection tube. The now dry RNeasy spin 
column had 30uL of RNase-free water added, and was centrifuged at 10,000 RPM for 1 
minute to elute the RNA. An additional 20uL of RNase-free water was added, and again 
centrifuged at 10,000 RPM for 1 minute to elute any remaining RNA. The tube 
containing the eluted RNA was then placed in an 8C refrigerator. 
The DNA was then eluted from the DNA spin column used earlier per Qiagen’s AllPrep 
DNA protocol.  
Quantification of DNA and RNA 
To ensure an adequate quantity of nucleic acid was present, a Nanodrop 
Spectrophotometer 2000 was utilized. After cleaning the device, 1uL of blank (RNase 
free water for RNA, Buffer EB for DNA) was pipetted to the pedestal to calibrate 
machine. Per standard protocol, 1uL of the nucleic solution from the previous extraction 
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steps was then pipetted onto the pedestal and measured, including the 260/280 ratio 
(absorbance of light a 260nm and 280nm), with a goal ratio of 1.8 – 2.2. 
Determination of quality of RNA 
To ensure an adequate quality of nucleic acid was present, an Agilent 2100 Bioanalyzer 
was utilized. After cleaning the device, the standard RNA ladder (Agilent) was gently 
thawed in an ice bath, which serves as a reference RNA to allow standardization 
between assays and ensure an external quality measurement. The electrode cleaner 
chip had 350 uL of RNase free water added and was placed in the Agilent 2100 
Bioanalyzer for 5 minutes. To prepare the gel matrix for the chip, 550 uL of RNA 6000 
Pico (Agilent) gel matrix was added to a supplied spin filter, and centrifuged at 
4000RPM for 10 minutes. Then 65uL of the gel matrix was combined with 1uL of RNA 
6000 Pico dye, and the mixture was centrifuged at 14,000 RPM for 10 minutes.  An 
RNA Pico chip was placed in the priming station, and 9 uL of dye-gel mixture was 
pipetted into the appropriate well. The chip was then primed by depressing 1mL of air 
from the syringe into the appropriate well to force the dye-gel mixture into the 
microtubes. After priming, 9 uL of the dye-gel mixture was then pipetted into each well, 
and 9 uL of RNA 6000 Pico conditioning solution and 5 uL of RNA 6000 Pico marker 
were then pipetted into their respective wells. In order to minimize secondary structure 
formation of the RNA, the sample was then heated to 70C for 2 minutes. After heating, 
1 uL of the RNA ladder and 1 uL of sample RNA were then pipetted into the correct 
wells, and vortexed in the Agilent vortex at 2400 RPM for 60 seconds. The RNA 6000 
Pico chip was then placed into the Bioanalyzer, and the software package was then 
instructed to “Run” the assay. The Bionanalyzer then determined the 
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“electropherogram” for the control markers, and the pattern of the 18S and 28S peaks. 
The software calculates an “RNA integrity number” (RIN), which correlates with the 
degree of RNA degradation and overall quality.  To ensure high quality data, only 
samples with both a B and non B fractions having a RIN number of at least 6.6 were 
taken to the next steps. 
RNA amplification and cDNA generation 
For preparation of gene expression profiling, the RNA from previous steps requires 
amplification. Into a sterile RNase free 0.5 mL microcentrifuge tube, ~1000ng (100ng 
minimum, 10ug maximum) of RNA was aliquoted, and enough nuclease free water to 
bring to 11 uL total volume was added. 
Following the protocol for Illumina TotalPrepTM RNA Amplification Kit instructions, the 
Reverse Transcriptase Master Mix is prepared as follows (multiply below by number of 
assays to be run): 
1. 1 uL of T7 Oligo(dT) primer 
2. 2 uL of 10X First Strand Buffer 
3. 4 uL of dNTP mix 
4. 1 uL RNase Inhibitor 
5. 1 uL of ArrayScript 
Into each RNA sample, 9 uL of Reverse Transcriptase Master Mix is transferred to bring 
to 20 uL total volume, and mixed well. The tube is then placed into the thermal cycler 
and incubated for 2 hours at 42C, allowing the first reaction to occur. After 2 hours 
elapse, the tube is placed on ice to stop the reaction.  
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The Second Strand Master Mix (Illumina TotalPrepTM RNA Amplification Kit, multiply 
below by number of assays to be run) was then prepared as follows: 
1. 63 uL of nuclease free Water 
2. 10 uL of 10x second strand buffer 
3. 4 uL of dNTP mix 
4. 2 uL of DNA Polymerase 
5. 1 uL of RNase H 
Into each sample from the Reverse Transcription first step, 80 uL of Second Strand 
Master Mix is transferred (total volume of 100 uL) and mixed well. The tube is placed 
into the thermal cycler and incubated for 2 hours at 16C. After 2 hours is completed, the 
sample tube is placed on ice to stop the reaction. To prepare for eventual sample 
elution, sufficient nuclease-free water to allow for at least 20uL for sample is preheated 
to 55C. The tube is removed from the ice bath and 250 uL of cDNA Binding Buffer 
(Illumina) was added to each sample, and mixed well. A new cDNA filter cartridge was 
placed in a wash tube supplied with the kit. The cDNA and Binding Buffer mixture were 
then pipetted on to the cDNA filter cartridge membrane, and centrifuged at 10,000 RPM 
for 1 minute, with flow through being discarded. To each cDNA filter cartridge, 500 uL of 
Wash Buffer (Illumina) was added and centrifuged at 10,000 RPM for 1 minute, with 
flow through being discarded. The cDNA filter cartridge was then transferred to a cDNA 
elution tube, and 20 uL of preheated nuclease free water was pipetted to the cDNA filter 
membrane. The membrane was allowed to stand at room temperature for 2 minutes, 
and then centrifuged at 10,000 RPM for 1.5 minutes. The flow through which contained 
the cDNA sample was then transferred into a PCR tube and placed on ice. 
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The IVT Master Mix (Illumina TotalPrepTM RNA Amplification Kit, multiply below by 
number of assays to be run) was then prepared as follows: 
1. 2.5 uL of T7 10x Reaction Buffer 
2. 2.5 uL of T7 Enzyme Mix 
3. 2.5 uL of Biotin-NTP Mix 
Into each cDNA sample, 7.5 uL of IVT Master Mix is transferred and mixed well. The 
mixture is then placed in the thermal cycler and incubated for 14 hours at 37C. After 14 
hours was completed, 75 uL nuclease free water was added to stop the reaction, and 
the sample was placed on ice. Prior to stopping the reaction, sufficient nuclease free 
water for at least 100uL per sample was preheated to 55C.  
To each sample, 350 uL of cRNA Binding Buffer (Illumina TotalPrepTM RNA 
Amplification Kit) was added, followed by 250 uL of 100% ethanol, which is mixed by 
pipetting. The resulting mixture was pipetted onto the filter of a cRNA Filter Cartridge 
and was centrifuged at 10,000 RPM for 1 minute, and the flow through was discarded. 
Each cRNA filter cartridge then had 650 uL of Wash Buffer (Illumina TotalPrepTM RNA 
Amplification Kit) added, and was centrifuged at 10,000 RPM for 1 minute, discard flow 
through with the flow through discarded. The filter was further dried by centrifuging at 
10,000 RPM for an additional minute, and then transferred to a cRNA collection tube. 
The cRNA filter then had 100 uL of preheated nuclease free water added and was 
incubated for 10 minutes in a 55C heat block. The heated tube was then removed, and 
centrifuged at 10,000 RPM for 1.5 minutes. The flow through containing the cRNA was 
then transferred to an eppendorf tube for storage at -80C. 
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cRNA Hybridization 
The Illumina Hybrization Oven was pre-heated to 58OC for at least 30 minutes, and the 
HYB and HCB buffer tubes were placed in the oven for 10 minutes to ensure any 
precipitation was dissolved. The cRNA was quantified with the nanospectrometer, and 
750ng was removed from the storage eppendorf tube for hybridization, with RNase-free 
water added to bring the total volume to 5uL. To the cRNA and RNase-free water 
mixture, 10uL of HYB buffer (Illumina) was added. The Hyb Chamber was then 
prepared following the protocol from Illumina, with Hyb Chamber inserts and Gaskets 
installed and 200uL of HCB buffer added into the 8 humidifying buffer reservoirs. A 
single HT12 Illumina BeadChip was then removed from its package for each 12 
samples to be hybridized, and placed in the Hyb Chamber Insert. A total of 15 uL of 
solution containing the cRNA was then loaded into the inlet port of the BeadChip and 
observed for evidence of air bubbles, which were recorded to allow for adequate 
interpretation of results. The Hyb Chamber inserts with BeadChips were then placed in 
the Hyb Chamber, and the Chamber was locked prior to being placed in the 
Hybridization Oven for between 14 – 20 hours.  
The Illumina High-Temp wash buffer was then prepared per protocol, and allowed to 
heat to 55OC overnight. The following day, the Wash E1BC buffer was prepared by 
adding 6mL of E1BC buffer to 2L of RNase-Free water. The Hyb Chamber was 
removed from the Hybridization Oven and disassembled. All BeadChips were removed 
and placed face-up in a beaker with Wash E1BC buffer. While submerged, the cover 
seal of the BeadChip was removed, and then the BeadChip was transferred to a 
submerged slide rack in a staining dish filled with Wash E1BC buffer. The slide rack 
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was then transferred to the Hybex Waterbath containing the High-Temp wash buffer 
and allowed to incubate for 10 minutes. After incubation, the slide rack was then 
immediately transferred to a staining dish with fresh Wash E1BC buffer and plunged in 
and out of the solution 5-10 times. The staining dish was then placed on an orbital 
shaker and agitated at room temperature for 5 minutes. The slide rack was then 
transferred to a new staining dish containing 100% ethanol, plunged in and out of the 
solution 5-10 times, and returned to the orbital shaker for an additional 10 minutes. The 
slide rack was then transferred to the staining dish with Wash E1BC buffer and plunged 
in and out of the solution 5-10 times, and returned to the orbital shaker for 2 minutes. 
The BeadChip wash tray was then prepared on the Rocker Mixer, with 4 mL of Block E1 
buffer (Illumina) added. Using tweezers, the BeadChip was removed from the slide rack 
and transferred into the BeadChip wash tray face up, ensuring the entire chip is covered 
by the buffer. The tray was then placed on the rocker and agitated at medium speed for 
10 minutes. The BeadChip was then grasped with tweezers and transferred to a fresh 
BeadChip wash tray 2 mL of Block E1 buffer containing a 1:1000 dilution of Cy3-
Streptavidin. The tray was then covered completely by placing an empty opaque ice 
bath container over the wash trays, and agitated gently for 10 minutes. The BeadChip 
was then removed from the wash tray and transferred with tweezers to a slide rack 
submerged in Wash E1BC buffer, and the slide rack was then plunged in and out of the 
solution 5-10 times. The staining dish containing the Wash E1BC buffer was then 
agitated gently for 5 minutes.  
To fully dry the BeadChips, the centrifuge was prepared with paper towels and allowed 
to rise to room temperature. The slide rack containing BeadChips was then removed 
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from the Wash E1BC buffer and centrifuged at 1400 RPM for 4 minutes, and transferred 
to a dry opaque storage container. The BeadChips were then taken to the University of 
Texas Medical Center Microarray facility and processed per manufacturer 
recommendations using an iScan device.  The resulting data files were then transferred 
back to our secure hard drive for further processing. 
Samples from normal tonsils from 24 children undergoing elective tonsillectomy were 
similarly prepared as single cell populations and viably frozen, and were depleted of B 
cells to generate NB fractions using the same approach as described above for FL 
samples. 
 
Flow cytometry  
Immunophenotyping of single-cell suspensions from FL lymph node biopsies and tonsils 
was done by 10-color, 12-parameter flow cytometry (LSR Fortessa, Becton Dickinson), 
using a panel of antibodies against CD3, CD4, CD8, CD20, CD16, CD56, CD68, 
CD45RA, CCR7, CXCR5, PD-1, and Foxp3 (all from Becton Dickinson) to determine 
various subsets of immune cellular elements.  For each subset, the relative percentage 
of total live cells was determined with the software package FlowJo version 9.3.3. 
Data Analysis 
GEP data and clinical information (prognostic factors and censored survival time data 
points) were downloaded from http://llmpp.nih.gov/follicularlymphoma from the Dave et 
al dataset.(63) 
Affymetrix gene expression data were handled essentially as originally detailed, with a 
few minor modifications. According to the most recent version of the annotation file, the 
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Affymetrix probe sets were matched to the corresponding gene symbols (Affymetrix 
U133 set, 2011/6/9), and the probe sets which did not correspond to a unique gene 
symbol annotation were removed. Finally, the median expression value of all remaining 
probe sets was selected as the expression value for further analysis of the 
corresponding individual gene. These data processing steps, principally the probe set 
with gene symbols matching, resulted in minor differences from the original analysis of 
Dave et al. From the initial IR-1 and IR-2 signatures, not all genes were retained in our 
analysis. The Cox model was used to identify either signature in multivariate models 
associated with survival outcomes up to 10 years after diagnosis. The log-rank test and 
Kaplan-Meier curves were employed to evaluate for differences in survival outcomes, 
using the Bioconductor “survival” software package. 
Data from the B and Non-B fractions from the sorting procedural steps described in this 
thesis were processed and normalized both together and independently, using methods 
previously described.(76) Raw bead-level fluorescence intensities for a given probe set 
was corrected by the model-based background correction method,(77) subtracting the 
mean value of negative control probes. Next, the intensities were trimmed by the 3-MAD 
method offered with Illumina software, quantile-normalized to equalize the distribution, 
and subsequently averaged resulting in a single value for a probe. A lower level of 
detection threshold value was also generated for each array from the negative control 
value distribution, which was subsequently used as the “floor” for experimental probe 
values. Next, probes were converted to gene symbols via the Bioconductor 
"illuminaHumanv4.db" software package. Standard methods of hierarchical clustering 
and heat mapping using Cluster and Treeview software packages were employed,(78) 
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and were used to screen for batching effects. When batching effects were suspected, 
they were addressed by discarding unsatisfactory samples, re-arraying samples, or 
using batch-effect correction software methods.(79) The samples from normal tonsils 
that were similarly prepared as our FL samples and underwent the GEP process to 
generate control NB fractions, and subsequently underwent a combined normalization 
along with the FL NB fractions to allow for comparisons. 
 
For the jointly-normalized dataset of combined B and non-B fraction array results, 
11,959 genes were expressed above background in 25% or more of samples. For each 
gene in this dataset, an NB-B fold-difference in expression between NB and B fractions 
was calculated as the average difference in paired log2-transformed values. For each of 
the B and NB fraction datasets normalized separately, genes were also eliminated that 
were not expressed above background in 25% or more of samples, and which were 
judged to represent contamination from the other fraction. After this, totals of 12,087 
and 10,652 genes remained in the NB and B gene expression profiles respectively.  
From the unsorted tumor GEP from the Dave et al. dataset, a master matrix of pairwise 
r values was determined from the Pearson correlation of all possible pairs from the 
14,383 genes with an average log2 expression value > 6. The master matrix then was 
iteratively filtered, depicted in Figure 2, to arrive at a final set of genes with a target 
number (N) or more correlations with other genes in the set exceeding a target 
correlation level of a positive r value threshold (Y). This process results in a list of genes 
with at least N correlations with the other genes in the set exceeding a positive r value 
of Y, of which N and Y can be modified for variable gene list creation to identify an 
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optimal fit. Visual inspection of the resulting hierarchically-clustered heat maps of the 
correlation matrix of r values of the remaining genes, as illustrated in the Results, was 
used to select the optimal values of N and Y, and to identify highly associated gene 
clusters of genes, which were then selected as gene signatures. These heat maps have 
a 45 degree axis of full correlation of a gene with itself (r=1), and result in a small 
number of large highly correlating on-diagonal clusters (red color). The clustering of 
genes, and thus their order in the list, is not determined by similarities in pairwise r 
values, but takes into account all respective vectors of their pairwise r values with all 
others genes including in the list. If two genes have similar vectors, and thus a similar 
pairwise r pattern with non-self genes, they would be ranked closely together in the list 
and thus their intersection pixels would be near the diagonal. If their vectors are not 
similar, and thus a dissimilar pairwise r pattern with non-self genes, they would not be 
ranked closely together and the red pixels which demonstrate their tight correlation with 
each other would be off the diagonal.  
These large clusters generally have significantly more than the minimal N number of 
correlations, and thus can be designated as a signature.  
Figure 2. Schematic of iterative filtering approach 
For the B and NB fractions, the initial filtering step 
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To deal with this significant roadblock, we employed the iterative filtering described 
above for its initial use in our analysis of the Dave dataset. We believed the weak 
correlations found in the separated tumor datasets were likely due to undesirable genes 
with low numbers of correlations which were obscuring those genes with higher 
numbers of correlations. By setting our iterative filtering criteria, as outlined in Figure 2, 
we were able account for this issue. 
To assign an attribution for a given signature from CMA, we tested the genes in the 
cluster for their correlation with previously published gene sets, or enrichment for 
containing genes from within these sets, via the hypergeometric distribution test.(80) 
The full methods of this test are published, but in brief can be described by Figure 3.  
 
Figure 3. Hypergeometric Distribution Test 
 
Legend: In this equation, p is the p value of enrichment. n is the number of 
genes included in a given cluster identified by our CMA. M is the number of 
genes in a previously published gene set that has a validated correlation with a 
biologic term, such as a cell type or cellular process. k is the number genes 
from n which are included in M. N is the total number of genes evaluated in the 
microarray studies and are members of one or more gene sets in a signature 
collection. 
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For the “self-correlation” matrix analysis of the separated FL tumor cell suspensions, the 
B and NB fraction datasets were normalized separately.  Genes that were not 
expressed above background in at least 25% of the dataset samples were removed. 
This filtering resulted in totals of 12,087 and 10,652 genes in the NB and B gene 
expression profiles, respectively. For each fraction, the initial master matrix of pairwise r 
values was filtered to retain only those genes with at least one r value > 0.8 with another 
gene. For the remaining genes, hierarchically-clustered heat maps of pairwise r values 
were then examined to identify clusters of genes that were likely to represent 
contaminating cells from the other fraction.  
 
In the correlation matrix of the NB fraction, 64 genes were identified to have an 
apparent origin from B cells (including CD19, CD22, TNFRSF13C (BAFFR), MS4A1 
(CD20), CD40, and CD79B), and were subsequently removed. In the correlation matrix 
of the B fraction, 886 genes were identified to have an apparent origin from non-B cell 
were similarly identified and removed. For both fractions, the remaining genes were 
then iteratively filtering as described above, with a visual inspection of clustered heat 
maps to select N and Y values, as illustrated in the Results, to identify highly associated 
gene clusters of genes, which were then selected as gene signatures. 
For “cross-correlation”, additional genes were eliminated from the B fraction that were 
more prevalent in the NB fraction, as defined as an NB-B fold-difference > 0, as 
determined in the jointly-normalized B and NB fraction data. The value for each NB 
signature, defined as the average value of its constituent genes, was then calculated 
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from the NB fraction of each sample. These values allowed the creation of correlation 
metric to quantify the correlation with the value of each remaining gene in the B fraction 
of corresponding samples: 
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The absolute values of this correlation metric would increase with increasing variation in 
expression of the B gene and/or the non-B signature, and with correlation (either 
positive or negative) between these two values. 
 
For those genes with multiple probes, the correlation metric values were averaged. 
Genes were then ranked from highest to lowest by their correlation metric value, which 
was subsequently utilized for gene set enrichment analysis (GSEA),(81) with standard 
methods and using default settings and the “Run Gsea on a Pre-Ranked gene list” 
option.. Gene sets originated from the Molecular Signatures Database v4.0 C2, C3, C5, 
C6, and C7 categories (http://www.broadinstitute.org/gsea/msigdb/index.jsp), and from 
custom gene sets created from relevant literature. 
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Chapter 3 
RESULTS 
Correlation matrix analysis of whole-tumor GEP data reveals signatures of 
immune cell types and biological features in FL tumors 
We utilized our correlation matrix analysis (CMA) technique to analyze GEP data from 
whole-tumor pretreatment biopsies of 191 FL patients, which were treated with a variety 
of therapies, from the Dave et al. dataset.(63) In contrast, the previous CMA work by 
Galon et al. utilized a small pre-selected list of T-cell relevant genes in their study of 
colon carcinoma.(82) Additionally distinct from our approach, Dave only assessed for 
correlation in genes which displayed a univariate correlation with overall survival (OS). 
In contrast, we took an unbiased approach, as detailed in the Methods section, to 
analyze the Dave dataset. We generated a master “correlation matrix” of pairwise 
Pearson correlation r values between all genes. This matrix was then iteratively filtered 
to arrive at a final set of genes with N equaling 5 or more r values (correlation with other 
genes in the set) exceeding a certain positive threshold of Y equaling r =0.7 for 
p<0.0001 in the 191 samples, resulting in a list of 468 genes. Data exploration involved 
selection of trial N and r value thresholds, followed by assessment of hierarchically-
clustered heat maps of the r values of final genes. This approach differs from typical 
heat maps of expression values as it is symmetrical, with the same genes in the same 
order in both rows and columns. Thus, the diagonal represents a self-correlation. The 
large red squares along the diagonal of Figure 3 identify groups of highly-correlated 
genes, containing >N number of genes, which are suitable candidates for designation 
as signatures. Goodness of heat maps was based on the degree of clustering of high r 
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values into discrete squares along the diagonal, and the degree to which genes in these 
squares plausibly represented immune cell types or biological features (e.g., 
proliferation).  
Analysis of the CMA heat map resulted in generation of eight signatures, which were 
subsequently analyzed for their constituent genes (figure 4). Based upon analysis of the 
genes which were included, the signatures were attributed to immune cell types or 
processes as described in the methods using the hypergeometric distribution test. Most 
of the genes in the attributed signatures were related to immune cell types in the tumor 
microenvironment, but some (Proliferation and Ribosomal) are features whose 
restriction to cell types, if any, are unclear.  
Figure 4. Whole-FL tumor correlation matrix reveals outcome-correlated signatures  
Legend: The self-correlation heat map shows pairwise r values of correlation for 
468 genes, selected by iterative filtering with N of 5 and Y of
the GEP data of Dave et al. The heat map is symmetrical, with the same order of 
genes in rows and columns, and hierarchical clustering of any two genes is based 
on the similarity of their pairwise r values with other genes in the matrix
values are colored according to the scale of the color bar. Large red squares along 
the diagonal identify groups of highly
with the attributions shown in yellow (NK = natural killer). 
A ninth group of 11 Y-chromosome associated genes, highly correlated due to the 
presence of male and female patients in the dataset, served as quality control. The 
levels of the Y-chromosome signature were distributed in a biphasic pattern which 
corresponded with the gender proportions in the Dave dataset
Figure 5. The Y-chromosome gene signature, defined by correlation matrix analysis of 
whole-tumor GEP data from Dave et al
Legend: Y-chromosome signature levels (average log2 lev
 0.7 for 191 samples in 
-correlated genes, which become signatures 
 
 (Figure 5). 
, identifies patient gender.  
els of signature 
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genes) are shown for each of the 191 patients, ranked by their patient identifier 
index number. The inset shows the degree to which signature levels, 
dichotomized at the log2 = 7 threshold, correctly identifies the gender of 
patients in the training and test sets of patients 
To explore the validity of the iterative filtering, we analyzed the CMA without iterative 
filtering to evaluate for the presence of organized signatures. A correlation matrix heat 
map of the 547 genes resulting from the same N and Y criteria but without iterative 
filtering (Figure 6) is not as well-organized, showing that exclusion of genes by iterative 
filtering helps in defining signatures. The lack of iterative filtering did not prevent 
identification of clustering genes, however there were more genes with a strong 
correlation (red) that were off the diagonal, with much larger and less tightly defined 
clusters. 
Figure 6. Correlation Matrix Heat Map Without Iterative Filtering 
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Signatures of immune cell types in FL tumors are predictive of outcome 
The signatures created with the CMA method were then evaluated in a multivariate Cox 
model to determine their correlation with survival outcomes (10-year OS) in the 164 
patients for which clinical parameters allowing for calculation of the IPI score data. We 
required that each signature was able to contribute significantly (p < 0.05) to the 
creation of the model, both with and without inclusion of the IPI. Based upon this 
requirement, a 3-signature predictive model was found (Table 1) that stratified patients 
into groups with significantly-different OS (Figure 7).  
Table 1. Multivariate Cox Model to determine the correlation with survival outcomes 
Overall model IPI T cell Macrophage Stroma 
7.602e-05  0.000585 (-0.764) 0.000106 (1.0389) 0.000919 (-0.6556) 
1.976 E-06 0.000691 (0.6996) 0.015134 (-0.5967) 0.001203 (0.9396) 0.014737 (-0.512) 
The p values for the individual parameters, and for the models overall (by the Wald test) 
are without parenthesis. The model coefficients, with positive values indicating 
parameters with an unfavorable effect on survival and negative values indicating a 
favorable effect on survival, in parenthesis.  
 
 
 
 
 
 
 
Figure 7.  Overall survival in the three signature model without the IPI 
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As a confirmatory finding, our model included signatures for T cells and macrophages 
that were respectively OS-favorable and OS-unfavorable in the Dave dataset, and no 
signature of apparent B-cell origin similar to the Dave dataset. Distinct from the Dave 
initial findings included a favorable effect of stroma, as previously reported in diffuse 
large B-cell lymphoma,(83) and that our signature genes were more clearly linked to T 
cells (e.g., CDs 2, 3, and 5; ZAP70; ITK; ICOS) and MP (e.g., CDs 14 and 63).  
Highly filtered data such as our signatures is often evaluated for the possibility of 
“overfitting”, which is ideally addressed by utilizing the model in an independent dataset. 
As there is no such available comparable dataset, we simulated testing our 3-signature 
model 10,000 times. Each test allowed determination of the coefficients in a randomly-
selected training set (50% of patients), with subsequent evaluation with the coefficients 
in the test set (50% of the patients). Utilizing this method of confirmation with inclusion 
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of the IPI to correct for patient factor imbalances between sets, the model was 
predictive (p < 0.05) in both the randomly-selected training and test sets in 90.5% of the 
10,000 tests, far greater than by chance (figure 8). This is not equivalent to an external 
dataset, but does lessen concerns regarding overfitting the data.  
Figure 8. Permutation test for robustness of the 3-signature+IPI model 
 
Legend: A) Schematic of the iterative procedure used. For the 164 patients 
for whom IPI data were available, each iteration involved random division into 
training and test sets of 82 patients each. For the training set patients, 
coefficients and the significance of correlation with overall survival (OS) were 
determined in a multivariate Cox model using levels of the IPI and the 3 most 
predictive CMA-defined signatures (Macrophage, T cell, and Stroma). The 
significance of correlation with OS was then determined in the test set, using 
the same coefficients. The process was repeated for a total of 10,000 times. 
B) Totals for the 4 possible outcomes, according to threshold of significance. 
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Features of immune cell types in the FL microenvironment revealed by CMA of 
separated tumor cell suspensions 
Although our correlation matrix analysis of the data from Dave et al. confirmed the 
previously reported importance of the microenvironment in FL, featuring opposing 
effects of macrophages and T cells, it did not provide further insights into important 
interactions between various cell populations. As the detection of GEP features of a 
particular cell type are likely obscured by the presence of other cell types in a 
heterogeneous sample,(84) the presence of B cells in whole-tumor biopsies may have 
limited or influenced our ability to examine the microenvironment, as well as its effects 
on B cells. To account for this limitation, and attempt to correct for it, we analyzed 
viably-frozen cell suspensions from untreated FL tumors, as described in the Methods 
section. Technically adequate results for both B and NB fractions from a given patient 
were achieved for 43 patient samples.  
CMA of NB fraction data (“self-correlation”), using N of 5 and Y of 0.8 (p<0.0001), 
resulted a highly organized heat map of 1097 genes (Figure 9). Without the potentially 
confounding presence of B cells, we could detect signatures of immune cell types aside 
from T cells and macrophages, including five highly self-correlating signatures of 
immune cell types and three highly self-correlating signatures of mechanistic processes 
(Signaling, IL10, and Proliferation). 
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Figure 9. Self Correlation heat map from the NB fraction 
Legend: The self-correlation heat map shows pairwise r values of correlation for 
1097 genes from GEP data of NB fractions from 43 FL tumors, selected by 
iterative filtering with N of 5 and Y of 0.8. Signature attributions are in white: Mac = 
macrophage, NK = natural killer, mDC = myeloid dendritic cell, FDC = follicular 
dendritic cell, Endo = endothelial, pDC = plasmacytoid dendritic cells. The 
signature marked with an asterisk is an FDC_Endo_Stroma-associated signature 
of 27 genes. 
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Of interest, plasmacytoid dendritic cells (pDC) manifested a small self-correlating gene 
signature, despite their typically only representing ~0.1% of all cellular events by flow 
cytometry (FACS) in FL. Some of our identified immune cell signatures were not 
attributable to a single cell type including macrophage (Mac) genes which were mixed 
with genes of natural killer (NK) and myeloid dendritic cells (mDC) in a Mac_NK_mDC 
signature. However, the Mac_NK_mDC signature did correspond to the presence of 
macrophages in the tumor samples. For confirmation, 39 samples from this dataset 
were analyzed with FACS for CD68+ cells. The proportion of CD68+ cells among non-B 
cells correlated highly with NB fraction levels of CD68 gene expression alone and with 
the Mac_NK_mDC signature (Figure 10)  
Figure 10. Flow cytometry of CD68 expression compared with Mac_NK_mDC signature 
and CD68 gene expression 
Legend: The expression of CD68 was determined as outlined in the Methods. In 
each tumor sample, the median expression value of the Mac_NK_mDC signature 
(left panel) and gene expression of CD68 (right panel) were correlated with the 
normalized CD68 flow cytometry data, showing good correlation. 
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The self-correlating T cell signature found in our NB fraction (TNB) was compared to 
signatures of effector T cells (Teff) and TFH cells previously published by us,(42) derived 
from GEP comparing flow cytometry defined Teff (PD1(PDCD1)intCXCR5int or 
PD1loCXCR5lo) vs. TFH cells (PD1hiCXCR5hi) in 3 independent FL samples. Although only 
18 genes were identified in both the 113-gene TNB signature created by our CMA and 
the 55-gene TFH signature from our prior work, we found a highly-significant positive 
correlation (r=0.944, p<0.001) in their levels in the NB fraction (Figure 11).  
Figure 11. The CMA-defined TNB signature compared with a previous TFH signature 
Legend: The median gene expression value for the TNB signature was determined 
from each patient and compared with the median gene expression value for the 
previously published TFH, from the same patient, showing excellent positive 
concordance. 
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 Based upon this strikingly high correlation, we conclude that TNB signature from the 
separated FL samples essentially represents a TFH signature.  
In Figure 9, the increased negative correlation manifested by green off-diagonal clusters 
of negative r values at the intersections between TNB and Mac_NK_mDC clusters 
suggests an inverse relationship between these cell types. This finding is confirmed by 
Pearson correlation between average levels of signature genes (r=−0.889, p<0.00001; 
Figure 12). Additional negative correlations were noted between the pDC and IL-10 
signatures, and between the Proliferation and both Signaling and Macrophage 
signatures. A positive correlation was observed between the Proliferation and T cells 
signatures in the FL microenvironment. 
Figure 12. The TNB signature compared with the Mac_NK_mDC signature 
Legend: The median gene expression value for the TNB signature was determined 
from each patient and compared with the median gene expression value for the 
Mac_NK_mDC signature from the same patient, showing strong negative 
concordance.  
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In theory, the attribution of a signature to a particular cell type could allow the 
conclusion that other genes in the signature, not previously reported to be associated 
with a specific cell type, are expressed by the putative cell of origin. This feature of self 
correlation matrixes applies to many genes, including chemokines, cytokines, and 
surface or intracellular molecules such as CCL19 from FDC/endothelial cells, and 
CCL3, CXCL16, FGL2, S100A8, S100A9, IL8, and TNFSF13B  from macrophages.  
A single signature for T cells was identified via our self correlation matrix, containing the 
genes CXCR5, PDCD1, ICOS, SH2D1A, CD40LG, CD200, BTLA, TIGIT, CD200 that 
are known to have varying levels of expression levels in distinct T cells subsets, such as 
Tfh, Th1, Tc1, and Treg.  
Comparison of follicular lymphoma microenvironment with the normal lymphoid 
microenvironment 
The interactions suggested by our correlation matrix analyses of FL patient tumor 
biopsies may not be unique to the FL microenvironment. To address the potential that 
immune cell types found in the FL microenvironment are qualitatively different from 
immune cells in a benign lymphoid organ, we performed GEP on the NB fraction of 
tonsils from 24 healthy children. In the NB fraction of the tonsils, we evaluated the TNB 
and Mac_NK_mDC signatures that we had previously generated in the FL NB fraction 
CMA. The individual genes from each signature were evaluated for their pairwise 
correlation in the benign tonsil NB fractions. In addition, we compared the expression of 
individual genes from these signatures in the NB tonsil population to the gene 
expression in the FL NB fractions. We found that the pairwise r values of the expression 
of the TNB cell and macrophage signature genes demonstrated a significantly weaker 
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correlation with each other in benign tonsils than in FL samples, as graphed in 
histograms from the two sample types (Figure 13).  The Pearson correlation r values 
are much lower in the NB fraction of tonsils than FL, which suggests that the T cells and 
macrophages (or NK or mDC cells) in the FL cells are distinct from their benign 
microenvironment counterparts.  
Figure 13. Histogram of TNB and Mac_NK_mDC signature correlation in FL and Tonsils 
Legend: The genes comprising the TNB signature and the Mac_NK_mDC were 
evaluated for correlation with other genes of in the signature. The histogram 
shows the tonsil (blue) samples had a much weak correlation than did the FL 
(orange) samples, demonstrating the differences between the microenvironment 
in the benign and malignant context. 
 
We concluded that this weaker correlation in the NB fraction of the benign tonsils is due 
to the possibility that our signatures correspond to with a cell type that is not normally 
found in benign lymphatic tissue. Based upon the above analyses, this indicates that 
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TFH and at least one of the Mac_NK_mDC cell types are qualitatively distinct in FL vs. 
the normal lymph node microenvironment.  
Similar findings were identified when the expression of previously determined 
signatures of effector T cells (Teff)(42) and TFH cells in FL and tonsil samples were 
compared. When the genes from these signatures were combined in a single heat map 
(Figure 14), we identified clusters which corresponded largely according to signature, 
and perfectly distinguished the FL samples from the tonsil samples. Furthermore, the 
samples from the NB FL population clustered into two distinct groups, predominantly on 
the basis of genes more associated with TFH cells. These data suggest that TFH cell 
infiltration of FL is not uniform, and may speak to the clinical heterogeneity seen in this 
disease.  
  
 49
Figure 14. Heat map comparing FL and tonsil samples for the expression of previously-
determined signatures of effector T cells (Teff) and TFH cells 
Legend: Mean-centered expression values are shown for genes (right) from the 
combined signatures distinguishing sorted Teff (green) and TFH (red) cells in 3 
previously-studied FL samples. The color bar indicates the fold value of expression 
relative to the mean of each gene. Data come from GEP of NB fractions of 43 FL 
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samples (red) and 24 normal tonsils (blue). Hierarchical clustering for similar 
variation in expression shows that genes cluster largely according to signature, and 
samples cluster perfectly according to sample group. The FL samples (red box) 
have 2 relatively distinct populations, one of which is highlighted (yellow box). 
“Cross-correlation” analysis identifies interactions between tumor cells and 
immune cells in the immune microenvironment 
A fundamental hypothesis underlying this thesis is that the biology of FL involves 
significant cross talk, either symbiotic and/or antagonistic, between FL cells and multiple 
benign immune cell types in the tumor microenvironment. To examine this hypothesis, 
we explored whether these interactions might be revealed by “cross-correlation” 
analysis, similar to the “self-correlation” analysis of the NB fraction described above, but 
involving correlation between levels of genes in one cell fraction (B or NB) and those of 
genes in the opposite fraction. Individual genes in each fraction for cross correlation  
were limited to those whose levels were at least as high as in the other fraction, to 
minimize the risk for identifying highly cross-correlated genes originating from cell types 
present in both fractions. Iterative filtering, using N of 8 and Y of 0.65 applied to genes 
of both fractions, produced a cross-correlation matrix of 226 B fraction genes and 278 
NB genes. The heat map of this matrix (Figure 15) clustered into non-overlapping paired 
groups of positively-correlated genes from each fraction, which were negatively-
correlated with each other. Evaluation of the gene lists via the hypergeometric 
distribution test showed that one group of NB fraction genes was characteristic of TFH 
cells. The positively-correlated group of B fraction genes which corresponds to the TFH 
genes contained many genes associated with proliferation, including CDC20, TOP2A, 
CCNB2, AURKA, AURKB, suggesting that tumor 
cells. This group of B genes also included SERPINA9, 
characteristic of germinal center B cells and 
genes was characteristic of macrophages. Upon evaluation
distribution test, the corresponding positively
not clear as to their implications, but overlapped significantly with several stem cell gene 
sets. 
Figure 15. Cross-correlation heat map of B vs. NB fraction 
In another approach to cross
compared to those of T cell signatures in the NB fraction; other signatures were not 
considered, since the methods used to prepare the fractions did n
potential presence of non-B, non
approach also differed in that the metric for comparison was not based solely on the 
Pearson r value, but also considered
signature as described in the 
TFH cells support proliferation of FL B 
previously reported to be 
FL.(85, 86) The other group of NB fraction 
 with the hyperge
-correlated group of B fraction genes were 
genes in FL tumors
-correlation, levels of individual B fraction genes were 
-T cells (such as macrophages) in both fractions. This 
 the variances of expression of e
Methods section. This approach created 
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correlation matrix which represents a set of independent correlations between the TNB 
signature and all B fraction genes. These values allow ranking of individual B fraction 
genes by their correlation with each NB signature. Table 2 shows results for the top 
individual 20 genes from the B fraction with the highest positive correlation with the T 
cell signature from the NB self correlation matrix. The B fraction gene with the strongest 
correlation with the T cell signature was SERPINA9, and several other genes 
associated with proliferation. We also identified genes previously described to be 
associated with proliferation (e.g., CDC20, TOP2A, AURKA, AURKB) were highly 
correlated, which imply that the NB T cell signature and/or tumor infiltrating TFH cells play 
a positive role in supporting B-cell proliferation, which here would mean malignant B-cell 
proliferation. As additional findings, B fraction levels of CCL17 and CCL22 were highly 
ranked, consistent with our previous observation that TFH induce these chemokines in FL 
B cells.(87)  
  
 53
Table 2. B genes having expressions with top 20 highest correlation with the T-cell NB 
signature 
 
In addition, we also examined the previously determined Teff and TFH signatures(42) in 
cross-correlation analysis between the B and NB fractions. B fraction genes that ranked 
most positively by the correlation metric with the TFH signature in the NB fraction, and 
most negatively with the Teff signature, were similar to those ranked positively with the 
TNB signature. This finding is consistent with our previous conclusion that the TNB 
signature is effectively a surrogate for a TFH signature. Further supporting our prior 
conclusion that TFH cells support FL proliferation, we also identified that the prior 
published TFH signature in the NB fraction correlated highly with B fraction levels of a 
proliferation signature identified by CMA of the B fraction. 
symbol Metric Rank
SERPINA9 0.79959191 1
CDC20 0.75779624 2
KIAA0101 0.51064588 3
TOP2A 0.50500598 4
TYMS 0.47261181 5
RPS4Y1 0.46898551 6
CCL22 0.45483511 7
IGJ 0.41632578 8
CCNB2 0.37535751 9
CAMP 0.33334485 10
UBE2C 0.32712714 11
KCNK12 0.30605593 12
ELL3 0.30466897 13
CCL17 0.29107038 14
GTSF1 0.27116205 15
AURKA 0.27057119 16
CDCA5 0.26226925 17
AURKB 0.25810637 18
KIFC1 0.25697333 19
SLC2A5 0.2460317 20
TFH,	CMA-defined
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Cross-correlation analysis was able to identify other previously reported biological 
interactions between FL B cells and immune cells. We previously identified that TFH  cells 
induce expression of the chemokines CCL17 and CCL22 by FL B cells.(87) In our cross 
correlation analysis, we identified that B fraction levels of these chemokines were highly 
ranked as positively correlated with NB fraction levels of both the TNB and TFH signatures. 
This finding may imply that the expression of these chemokines by malignant FL B-cells 
likely plays an important role in shaping the FL immune microenvironment, including 
recruitment of TFH cells. We also found a positive correlation between individual values 
of the TNB signature in NB fractions and values of CCL22 and CCL17 in their 
corresponding B fractions, is shown in Figure 16. 
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Figure 16. Correlation of CCL17 and CCL22 in the B tumor fraction with the TNB 
signature in the NB fraction 
Legend: The individual genes CCL17 and CCL22 were determined in the B 
tumor fraction from each patient and compared with the median expression value 
of the TNB signature from the NB fraction in the same patient, showing good 
concordance. 
To allow for further interpretation of the cross correlation matrix, we employed Gene Set 
Enrichment Analysis (GSEA)(88) which we conducted by ranking B fraction genes 
based upon their correlation with the TNB signature. We identified previously known 
findings, including that ranked B fraction genes based upon correlation with the T cell 
signature had a strong positive enrichment for gene sets related to proliferation. 
However, our GSEA also positively enriched two gene sets which are based the 
comparison of germinal center (GC) B cells to cells at neighboring stages of 
differentiation, including before (naïve B cells; GSE12366_GC_VS_NAIVE_BCELL_UP) 
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or after (memory B cells; GSE12366_GC_VS_MEMORY_BCELL_UP) the GC 
stage.(89) This finding was not anticipated as all samples were from FL, which is known 
to correspond to the GC stage. This finding suggests that the FL samples with B 
fractions that have strong similarities to normal GC B cells are those with increased TFH 
cells. Another possible mechanism for this finding may be that TFH cells are associated 
with FL variants with a greater reliance on B-cell receptor (BCR) signaling, as a 
signature comparing splenic B cells from wild type mice against BTK-mutant mice 
(GSE2826_WT_VS_XID_BCELL_UP)(90) was also enriched by correlation with the TNB 
cell signature.  
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Chapter 4 
DISCUSSION 
The creation and use of signatures to interpret GEP data is a common practice as it 
allows for conceptualization of the complex gene interactions that occur in normal and 
diseased cells. When a signature is determined in a given context, it is generally 
applicable to other datasets, at least for hypothesis generation. This includes signatures 
found in the public repository Molecular Signatures Database. The novel technique of 
correlation matrix analysis (CMA), assisted by iterative filtering, is distinctive in that it is 
able to identify groups of coordinately expressed genes from the data themselves, 
which thus fit the data well. This allows for a “dimension reduction” of the GEP data, 
which can greatly assist analysis.  
The work in my thesis is an unbiased use of all potential genes for CMA, as opposed to 
previous applications of CMA, which have generally utilized a preselected set of genes, 
for which the proper attribution to a given cell type is known. Our novel approach poses 
new challenges, the first being whether signatures can be identified that are discrete 
(i.e., composed of genes that correlate more highly with each other than with genes of 
other signatures) and biologically plausible rather than random collections of covariant 
genes. The use of iterative filtering, which we developed for this study, contributed 
greatly to our ability to identify discrete signatures. Although results depended on the N 
and Y criteria used for the iterative filtering, we found that the number of signatures was 
relative small, and that their constituent genes generally provided a clear basis for 
attribution. In other words, at least in FL, there is substantial “structure” to the data, 
reflecting the presence of well-defined immune cell types and highly-orchestrated 
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biological processes (such as proliferation) in the tumor. In other words, just as there 
are not an unlimited number of different cell types in an FL tumor, so there are not an 
unlimited number of signatures. 
In the dataset from the landmark study of intact whole-tumor of FL GEP by Dave, our 
method of CMA was able to identify multiple groups of coordinately expressed genes 
which we could attribute to biologically relevant immune cell subsets and other essential 
cellular function programs. Our signatures included the OS-favorable T cells and OS-
unfavorable macrophages, similar to the initial non-CMA findings. We did not consider 
these similarities to be surprising, as the initial group used hierarchical correlation, 
similar to the pairwise correlation we used, to group genes into a total of 10 signatures, 
2 of which were T cells and macrophages. However, their data analysis did not 
incorporate all potential genes and thus had an introduction of bias. The genes that 
Dave et al selected for clustering had to first meet a minimum level of significance (p < 
0.1) with OS in a univariate correlation analysis. In contrast, our analysis included all 
genes, and performed correlation with OS only on CMA-defined groups of genes, or 
signatures. This distinction likely resulted in our CMA-defined T cell and macrophage 
signatures including a greater number of total genes, and a greater number of genes 
that are characteristic of their putative cell of origin. In our T cell signature, we identified 
genes associated with CDs 2, 3, and 5, ZAP70, ITK, and ICOS. In our macrophage 
signature, we identified genes associated with CDs 14 and 63, suggesting biologic 
plausibility. Our analysis also identified a stroma-related signature which was OS-
favorable, consistent with the findings of others in another subtype of NHL, diffuse large 
B-cell lymphoma.(83) Together, these findings lead us to conclude that our method of 
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signature creation is valid and can create biologically relevant signatures that are 
attributable to immune cell subtypes and other cellular processes. 
Our CMA-defined T cell signature from the Dave et al data was not specific to a 
particular T cell subset or physiologic state, comparable to original analysis. As a result 
of this caveat, our signature is limited in mechanistic implications. However, our CMA of 
the separated untreated FL tumor samples, specifically the NB fractions resulted in our 
TNB signature, larger than that of the T cell signature of Dave. Based on further 
correlative analyses, we concluded that our TNB signature is effectively representative of 
TFH cells. Not all tumor infiltrating T cells in FL are TFH cells, as has been shown by 
immunostaining and other analyses.(87) However, our CMA-defined T cell signature 
implies that TFH cells are the most consistent T cell subset across our FL biopsy 
samples, although varying in their frequency. Based upon review of the literature, we 
did not find this to be unexpected as FL is often described as originating from the 
normal germinal center of benign lymph nodes in which TFH cells play an essential role. 
Our findings regarding TFH cells were also unsurprising as we found that TFH cells were 
increased in the NB fraction of FL tumors when compared to reactive lymph tissue.(91) 
However, our TNB signature did not have significant applicability in the NB fractions 
isolated from the tonsil samples, which we concluded to imply that the TFH in FL and the 
normal lymph node microenvironment have distinctive qualitative differences. 
Based upon our conclusion that T cells, specifically TFH cells, have significant self 
correlation in FL samples, it is logical to assume that this may occur due to interactions 
occurring between FL tumor B cells and immune cells in the tumor microenvironment. 
To further support this hypothesis, we identified “cross-correlations” between genes 
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expressed in isolated malignant B cells from FL and the level of expression of NB 
fraction signatures. The nature of these relationships, antagonistic or tumor promoting, 
is less clear, but their existence suggest a bi-directional interaction on and by both B 
and non-B cells. Pangault et al. also performed GEP on sorted FL tumors or reactive 
lymph nodes and tonsils, utilizing different methods than ours including positive 
selection of cells during isolation. Their analysis generated “interfaces”, defined as sets 
of genes which could distinguish B and NB fractions.(92) Their use of this analytic 
technique concluded that TFH cells were responsible for the majority of the differences 
between the FL and non-FL interfaces. In addition, they also concluded that the TFH cell 
population affected B cells. Further supporting their implication of the role of TFH, they 
also found that IL-4 expression was distinctive for FL TFH when compared with normal T 
cells. The FL B cells demonstrated effects of this TFH IL-4 signaling, including high 
expression of IL4I1, an IL-4 target gene whose B fraction levels were highly ranked by 
metric correlation with TNB signature levels in our data. Ame-Thomas et al also identified 
IL-4 as the most highly expressed gene by FL TFH cells as compared to tonsil TFH cells. 
In addition, they also found that antibodies which block CD40L or IL-4 were able to 
reduce the ability of autologous FL TFH cells to promote survival via protection of tumor B 
cells from spontaneous apoptosis.(93) Myklebust et al. found that FL TFH cells can have 
IL-4 production induced by stimulation, but are insensitive to STAT6 phosphorylation via 
IL-4, and thus can avoid a negative feedback loop.(73) Lastly, Kiaii et al. identified 
several genes, including PMCH, ETV1, and NAMPT, that were more highly expressed 
in CD4+ and/or CD8+ T cells from FL samples than from tonsils. In normal T cells co-
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cultured with FL B cells, but not with tonsillar B cells, these genes were up-regulated 
implying a distinctive FL-T cell interaction.(94) 
Recent innovative studies using multiparameter confocal immunofluorescent 
microscopy have evaluated the FL microenvironment. This technique allows for 
evaluation of multiple parameters, similar to flow cytometry, without disruption of the 
tissue architecture, similar to immunohistochemistry. These analyses support our 
findings that TFH cells have effects on FL B cells, including promotion of their 
proliferation, as they demonstrate enrichment of FL tumor follicles for TFH cells, defined 
as CD4+/PD1+/ICOS+ cells. They confirmed these cells were TFH cells by protein 
expression of BCL6, the master TFH transcription factor.(95) The multiparameter 
microscopy also found that 42% of proliferating tumor B cells, defined as Ki67+, were in 
direct contact with TFH cells including synapse formation.  
An additional implication of this FL B cell – TFH cell interaction was shown with cross-
correlation with NB fraction levels of the TNB signature, and those from a previously-
defined TFH signature, suggesting induction of CCL22 and CCL17 in FL B cells by 
infiltrating TFH cells. This supports a conclusion of our previous work(87) that identified 
CCL17 and CCL22 levels to be significantly higher in both serum and tumor B cells from 
FL patients when compared with healthy donors. We also previously found that TFH cells 
can strongly induce CCL17 and CCL22 production by FL tumor B cells through IL-4 and 
CD40L. Lastly, we also previously demonstrated that cultured FL supernatant could 
induce migration of both IL-4-producing T cells and regulatory T cells (Treg), more so 
than IFN-gamma-producing T cells.(87) Other investigators have previously found 
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similarities between TFH cells and subsets of Treg cells (Follicular Treg, TFR), both which 
express CD4+/CXCR5+/ICOS+ cells in FL.(91, 93) 
We found substantial differences in our CMA results of the whole tumor Dave dataset 
and of the separated 43 FL samples from our dataset. These differences included the 
gene lists selected by our iterative filtering, with only 87 genes overlapping between the 
Dave list (468 genes) and from our NB fraction (1097 genes). Both datasets yielded T 
cell and macrophage-related signatures generated from CMA, of which there were few 
genes in common, although more than expected by chance. These differences in CMA 
do not imply that the datasets are non-compatible, as some of the differences could 
result from whole vs. sorted tumors. Another potential explanation for these differences 
could be the use of the Affymetrix microarray platform for Dave, and Illumina for our 
dataset. Another potential limitation of our approach is illustrated by our identification of 
signatures of rare cell types including FDC and pDC in the NB fraction, but inability to 
identify unique signatures of other immune cell subsets (e.g., macrophages, NK cells, 
and mDC), or identify an attributable signature of others which would be expected to be 
present at low levels (e.g., Tregs, and Teff subsets like TH1, TH2, and TH17). An explanation of 
this limitation may be the potential similarities or overlaps in the expression of genes 
between these cell types, or because they may display significant heterogeneity across 
patient samples. 
The work in this thesis confirms the findings of others and contributes additional data to 
support the hypothesis of a symbiotic feed-forward relationship between the 
microenvironment and FL cells. In this interaction, TFH cells induce both proliferation and 
production of CCL17 and CCL22 by FL tumor cells, which subsequently leads to 
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attracting Treg and IL-4-producing T cells. These tumor-infiltrating benign immune cells 
further stimulate chemokine production, and perpetuate additional pro-tumor cell 
recruitment.  
In conclusion, the results of my thesis project suggest that the novel technique of CMA 
may have broad applicability to characterize interactions found in cancer biopsies, and 
shed light on complex but potentially targetable abnormal interactions. Our CMA 
method can define signatures of both cancer cells, as well as infiltrating benign immune 
and stromal cell subsets in the tumor microenvironment. These novel, or modified from 
prior, signatures may subsequently be utilized to characterize and potentially 
understand these tumor-microenvironment interactions, determine the prognostic 
impact of the presence or absences of microenvironmental cell types, discover novel 
therapeutic targets for future study with clinical trials, and to identify subsets of patients 
with a potential increased likelihood of response to CMA signature informed targeted 
therapies. 
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Chapter 5 
STRENGTHS AND WEAKNESSES 
This thesis is the first attempt at using CMA paired with separated cell population 
analyses in follicular lymphoma. The significant strengths of my project include its 
unique ability to determine the complex interactions between various cell types in the 
tumor microenvironment, and thus determine not just which cell types are present, but 
are also exerting an influence on other types.  
The work in this thesis demonstrates that the novel approach of CMA can discern 
signatures consisting of genes attributable to various immune cell types in FL. We 
believe that this approach can be utilized to implicate mechanisms which are essential 
to FL biology, and could be applied to other cancer types for similar analyses. We 
believe that our TNB signature was validated by its high correlation in our analyses with a 
previously determined TFH signature from cells sorted with flow cytometry.  
However, it is important to note there are several limitations to the work detailed in this 
thesis, including the technique of CMA and the confidence of the results. By definition, 
CMA requires multiple samples in order to evaluate for correlations, and becomes 
increasingly powerful with an increasing sample size. The implication of this 
dependence on sample size is that findings from CMA, including the signatures that it 
can generate, may be specific to the sample set and thus not applicable globally, 
especially with smaller or highly selected datasets. Furthermore, the determination of 
the variables of N and Y for iterative filtering is subjective, and may have implications on 
the ability of the conclusions to be applied to other datasets. The evaluation of 
goodness of correlation matrix heat maps is also admittedly operator-dependent. 
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However, in our analysis, we found that for a particular dataset, the CMA generated 
signatures did not change significantly as the variables were modified.  
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Chapter 6 
FUTURE DIRECTIONS 
The work in this thesis suggests previously unexplored potential targets for therapeutic 
intervention. Agents which target the pro-tumor B-TFH interaction which we have 
demonstrated to be present and robust include antibodies which block the interaction 
between CD40L and CD40, which have been tested in clinical trials. To date, these 
agents have had only modest efficacy in patients with relapsed FL,(96) however this 
was as a single agent. In isolation, interfering with the CD40L and CD40 interaction, or 
other pro-tumor B-TFH interactions, may not be sufficient for an impressive clinical 
response as they affect one of the many important interactions between FL B and TFH 
cells, leaving others (e.g., IL-4) unaffected. It is doubtful that this complex interaction 
would collapse if a single portion is interrupted, as has been seen in other complex 
network interactions. Removal of a single interaction of TFH and B cells, even if it appears 
to be essential, is likely insufficient to cause significant damage to a complex network 
such as the cancer-microenvironment interaction.(97) Therefore, we hypothesize that 
agents which target and potentially kill TFH cells directly may need to be developed in 
order to eliminate their pro-tumor effects, and combined with other therapeutic agents 
for maximal effect. Our TNB signature from this thesis may be utilized to identify a subset 
of FL patients most likely to benefit from eradication of TFH cells due to their symbiotic 
interaction in that subset. Similarly, other signatures derived from our CMA methods 
may help to identify additional patients likely to benefit from microenvironment-directed 
targeted therapies, including anti-CSF-1R therapies in patients with high levels of 
macrophage signatures and anti-PD-1 therapies in patients with high levels of the Teff 
 67
signature.(42, 98) This hypothesis would need to be formally evaluated in clinical trials, 
as animal models which accurately depict this complex interaction are currently lacking. 
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